Clinical trial
AZD1152 in Patients With Advanced Solid Malignancies-Study 1
NCT00497731 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00497731 |
|---|---|
| Title | AZD1152 in Patients With Advanced Solid Malignancies-Study 1 |
| Official title | A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a 2 Hour Intravenous Infusion on Two Dose Schedules in Patients With Advanced Solid Malignancies |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumors |
| Intervention type | Drug |
| Interventions | AZD1152 |
| Enrollment | 70 |
| Start date | May 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Jul 9, 2007 |
| Last update posted | Jun 22, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: